Skip to main content
CI

Circio

Oslo, Norway
Last funding
$31.5M
Post-IPO EquityJun 2026

Targovax develops active immunotherapy in the form of cancer vaccines for application in post-operation treatments.

Backed byInnovation NorwayBirk VentureRadium Hospital Research FoundationAtlas Special OpportunitiesAlgot Invest

About Circio

How much funding has Circio raised?

Circio has raised $31.5M in total funding. The most recent round was Post-IPO Equity. The last funding was announced in June 2026.

Who are Circio's investors?

Circio's investors include Innovation Norway, Birk Venture, Radium Hospital Research Foundation, Atlas Special Opportunities, Algot Invest.

Where is Circio headquartered?

Circio is headquartered in Oslo, Norway.

What does Circio do?

Targovax develops active immunotherapy in the form of cancer vaccines for application in post-operation treatments.

What stage is Circio at?

Circio is at the Post-IPO Equity stage.

Cite this page

Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .

MLA
"Circio — Funding & Investors." VCBacked, June 10, 2026, https://www.vcbacked.co/company/circio. Accessed November 21, 2026.
APA
VCBacked. (2026). Circio — Funding & Investors. Retrieved November 21, 2026, from https://www.vcbacked.co/company/circio
Wikipedia (cite web)
{{cite web |title=Circio — Funding & Investors |url=https://www.vcbacked.co/company/circio |website=VCBacked |access-date=November 21, 2026}}

Profile data sourced and verified per the VCbacked methodology · Last funding round dated

Work at Circio? Request a listing update

Founder contacts
m***@circio.com
linkedin.com/in/●●●●●●
Emails, phones & LinkedIn · 41,000+ verified contacts
Get instant access →